

Lihui Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5524498/publications.pdf>

Version: 2024-02-01

33
papers

1,313
citations

304743

22
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

2070
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. <i>Drug Resistance Updates</i> , 2022, 61, 100821. | 14.4 | 20 |
| 2 | An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. <i>Molecular Cancer</i> , 2022, 21, 106. | 19.2 | 20 |
| 3 | Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5519-5534. | 6.4 | 26 |
| 4 | Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. <i>Drug Resistance Updates</i> , 2021, 57, 100770. | 14.4 | 59 |
| 5 | Multi-functional DNA-conjugated nanohydrogels for aptamer-directed breast cancer cell targeting. <i>New Journal of Chemistry</i> , 2021, 45, 20410-20418. | 2.8 | 3 |
| 6 | Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of TERT) /Overlock 10 Tf | 2.8 | 7 |
| 7 | DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy. <i>Cancers</i> , 2020, 12, 2123. | 3.7 | 124 |
| 8 | Histone methyltransferase and drug resistance in cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 173. | 8.6 | 44 |
| 9 | Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. <i>Molecular Cancer</i> , 2020, 19, 134. | 19.2 | 44 |
| 10 | The combination of disulfiram and copper for cancer treatment. <i>Drug Discovery Today</i> , 2020, 25, 1099-1108. | 6.4 | 95 |
| 11 | 5-Hydroxyindole-Based EZH2 Inhibitors Assembled via TCCA-Catalyzed Condensation and Nenitzescu Reactions. <i>Molecules</i> , 2020, 25, 2059. | 3.8 | 5 |
| 12 | Epigenetic synthetic lethality approaches in cancer therapy. <i>Clinical Epigenetics</i> , 2019, 11, 136. | 4.1 | 26 |
| 13 | Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2019, 10, 400. | 6.3 | 29 |
| 14 | Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC. <i>Bioorganic Chemistry</i> , 2019, 86, 696-704. | 4.1 | 3 |
| 15 | Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors. <i>Frontiers in Oncology</i> , 2019, 9, 194. | 2.8 | 73 |
| 16 | Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. <i>Cell Death and Disease</i> , 2018, 9, 129. | 6.3 | 54 |
| 17 | PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway. <i>European Journal of Pharmacology</i> , 2018, 821, 29-38. | 3.5 | 7 |
| 18 | Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2018, 827, 1-12. | 3.5 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer. <i>RSC Advances</i> , 2018, 8, 33464-33472. | 3.6 | 6 |
| 20 | Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. <i>Genes</i> , 2018, 9, 633. | 2.4 | 26 |
| 21 | Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. <i>Cell Death and Disease</i> , 2017, 8, e2746-e2746. | 6.3 | 93 |
| 22 | Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 974-983. | 6.4 | 47 |
| 23 | Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells. <i>Oncotarget</i> , 2016, 7, 58516-58530. | 1.8 | 84 |
| 24 | Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo. <i>Chemico-Biological Interactions</i> , 2016, 249, 64-70. | 4.0 | 6 |
| 25 | Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1916-1928. | 3.6 | 20 |
| 26 | Dual-responsive mPEG-PLGA-PGLu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: An in vitro and in vivo evaluation. <i>Acta Biomaterialia</i> , 2015, 16, 156-168. | 8.3 | 74 |
| 27 | Minor cytotoxic cardenolide glycosides from the root of <i>Streptocaulon juvenas</i> . <i>Steroids</i> , 2015, 93, 39-46. | 1.8 | 5 |
| 28 | Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: Synthesis, anti-invasive and anti-angiogenic properties. <i>European Journal of Medicinal Chemistry</i> , 2015, 89, 88-97. | 5.5 | 50 |
| 29 | Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach. <i>Oncotarget</i> , 2015, 6, 9740-9755. | 1.8 | 27 |
| 30 | Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 81, 47-58. | 5.5 | 32 |
| 31 | A novel small molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. <i>Molecular Oncology</i> , 2014, 8, 1640-1652. | 4.6 | 38 |
| 32 | Design, synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 257-269. | 5.5 | 37 |
| 33 | Pterostilbene attenuates lipopolysaccharide-induced learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 92-102. | 4.8 | 79 |